News | May 03, 2024
Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The demand in Africa for COVID-19 vaccines has declined
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Combination shows consistent benefit across prespecified post-progression outcomes
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Subscribe To Our Newsletter & Stay Updated
